Anixa Biosciences, Inc. reported earnings results for the first quarter ended January 31, 2024. For the first quarter, the company reported net loss was USD 3.26 million compared to USD 2.32 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.08 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.47 USD | -1.20% |
|
0.00% | -36.34% |
06-24 | Anixa Biosciences Says Sixth Patient Treated in Phase 1 Ovarian Cancer Study | MT |
06-24 | Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.34% | 79.06M | |
+38.36% | 52.73B | |
+39.33% | 39B | |
-8.63% | 38.52B | |
+25.46% | 30.38B | |
-11.17% | 26.39B | |
+11.44% | 26.08B | |
+45.09% | 14.15B | |
+32.93% | 12.6B | |
-5.30% | 11.51B |
- Stock Market
- Equities
- ANIX Stock
- News Anixa Biosciences, Inc.
- Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024